![]() ![]() I strongly believe that taking many measurements simultaneously, like a whole pathway or a whole assembly of proteins, would lead to much better diagnoses than what we have now.Īnother aspect is that people are usually tested for one disease, but most people have co-morbidities which can be caught by using mass spectrometry in a systems biology-based approach. ![]() The bigger reason to use mass spectrometry is that you can measure many things at once. It could be made much more precise with mass spectroscopy-based techniques because they are a lot more digital. For example, when faced with diabetics with high triglycerides, the laboratory scientists will know that the antibody will stop working, but the test doesn't say that. The technical questions are about how accurate these are. Rapid Proteome Analysis with timsTOF Pro - Professor Matthias Mann - Max Plank Institute Play Why do you feel it's important to see more proteomics-based techniques in clinical environments?Ĭlinics rely heavily on laboratory tests, but it's usually one protein or one small molecule. I then followed the electrospray downstream, from characterizing single proteins to protein complexes, and then increasingly complex assemblies to whole cells, which I analyze today.įollowing this, I began working on understanding how to create the ions, to how they can be measured, and then to increasing separation and speed to keep up with the complexity. ![]() I am educated as a physicist and a mathematician originally and started working with John Fenn on electrospray. What sparked your interest in fundamental research while working in John Fenn’s lab? Instead, the simultaneous analysis of many components in a cell and the systems biology aspects of shotgun proteomics appealed to me. When proteomics came along, many people were focusing on the shape of 2D gels, but this didn’t interest me. I came from the mass spectrometry field before proteomics even existed. What first attracted you to the field of proteomics? ![]() In this interview, Professor Matthias Mann discusses his work in the field of proteomics, and explains why applying proteomics-based technologies such as timsTOF to the clinic could accelerate the diagnosis and prediction of human disease. Thought Leaders Professor Matthias Mann The University of Copenhagen & The Max Planck Institute of Biochemistry ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |